Ibrutinib inhibits BTK-driven NF-κ B p65 activity to overcome bortezomib-resistance in multiple myeloma

Cell Cycle

Volumn 14, Issue 14, 2015, Pages 2367-2375

  Murray, Megan Y ^a   Zaitseva, Lyubov ^a   Auger, Martin J ^b   Craig, Jenny I O ^c   MacEwan, David J ^d   Rushworth, Stuart A ^a   Bowles, Kristian M ^a,b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bortezomib; BTK; Drug resistance; Ibrutinib; Multiple myeloma; NF kB

Indexed keywords

BORTEZOMIB; BRUTON TYROSINE KINASE; IBRUTINIB; MICRORNA; TRANSCRIPTION FACTOR RELA; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR RECURRENCE;

BORTEZOMIB; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MICRORNAS; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROTEASOME INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR CELLS, CULTURED;

EID: 84938199929     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2014.998067     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts &Figures 2014. (2015). 1st ed. [ebook] Atlanta, Georgia: American Cancer Society, p. 4. Available at: http://www. cancer. org/research/cancerfactsstatistics/cancerfactsfigures2014/[Accessed 6 May 2014].
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-39; PMID: 19541364; http://dx. doi. org/10. 1016/S0140-6736(09)60221-X.
3. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003; 95: 845; PMID: 12813164; http://dx. doi. org/10. 1093/jnci/95. 12. 845.
4. Palumbo A, Attal M, RousselM. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 2011; 17: 1253-63; PMID: 21411441; http://dx. doi. org/10. 1158/1078-0432. CCR-10-1925.
5. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Seminars Hematol 2012; 49: 228-42; PMID: 22726546; http://dx. doi. org/10. 1053/j. seminhematol. 2012. 04. 010.
6. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J-P, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-72; PMID: 21430775; http://dx. doi. org/10. 1038/nature09837.
7. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-6; PMID: 22529291; http://dx. doi. org/10. 1182/blood-2012-01-405977.
8. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012; 120: 1067-76; PMID: 22498740; http://dx. doi. org/10. 1182/blood-2012-01-405985.
9. Magrangeas F, Avet-Loiseau H, Gouraud W, Lode L, Decaux O, Godmer P, Garderet L, Voillat L, Facon T, Stoppa AM, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013; 27: 473-81; PMID: 22874878; http://dx. doi. org/10. 1038/leu. 2012. 226.
10. Chen Z, Orlowski RZ, Wang M, Kwak L, McCarty N. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 2014; 123: 2204-8; PMID: 24425802; http://dx. doi. org/10. 1182/blood-2013-07-517136.
11. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17: 1264-77; PMID: 21411442; http://dx. doi. org/10. 1158/1078-0432. CCR-10-1805.
12. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012; 120: 3260-70; PMID: 22932796; http://dx. doi. org/10. 1182/blood-2011-10-386789.
13. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, et al. Molecular basis of bortezomib resistance: proteasome subunit {b}5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489-99; PMID: 18565852; http://dx. doi. org/10. 1182/blood-2007-08-104950.
14. Stessman HA, Mansoor A, Zhan F, Linden MA, Van Ness B, Baughn LB. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma. PLoS One 2013; 8: e77608; PMID: 24204892; http://dx. doi. org/10. 1371/journal. pone. 0077608.
15. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, et al. Frequent Engagement of the Classical and Alternative NF-kB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma. Cancer Cell 2007; 12: 115-30; PMID: 17692804; http://dx. doi. org/10. 1016/j. ccr. 2007. 07. 004.
16. Murray MY, Auger MJ, Bowles KM. Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans 2014; 42: 4; http://dx. doi. org/10. 1042/BST20140126.
17. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2013; 25: 106-12; PMID: 22975686; http://dx. doi. org/10. 1016/j. cellsig. 2012. 09. 008.
18. Murray MY, Rushworth SA, Zaitseva L, Bowles KM, MacEwan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 2013; 12: 2144-53; PMID: 23759586; http://dx. doi. org/10. 4161/cc. 25251.
19. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kB and underlies its chemo-resistance. Blood 2012; 120: 5188-98; PMID: 23077289; http://dx. doi. org/10. 1182/blood-2012-04-422121.
20. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann T, Anderson K. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NFkappa B. Blood 1996; 87: 1104-12; PMID: 8562936.
21. Lu S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res 2013; 1 (1): 13; PMID: 24252210; http://dx. doi. org/10. 1186/2050-7771-1-13.
22. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B, Arteaga HJ, Nore BF, Smith CI. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008; 111: 4617-26; PMID: 18292289; http://dx. doi. org/10. 1182/blood-2007-10-121137.
23. Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-87; PMID: 22689860; http://dx. doi. org/10. 1182/blood-2011-12-396853.
24. O'Brien S, Furman R, Coutre S, Burger J, Blum K, Sharman J, Flinn I, Grant B, Heerema N, Johnson A, et al. The Bruton's tyrosine kinase inhibitor Ibrutinib is highly active and tolerable in relapsed or refractory (R/R) and treatment naïve (TN) CLL patients, updated results of a phase IB/II study. Haematologica 2012 97: 256, abstr 0542.
25. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 2014; 123: 1229-38; PMID: 24307721; http://dx. doi. org/10. 1182/blood-2013-06-511154.
26. Khan W. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001; 23: 147-56; PMID: 11444380; http://dx. doi. org/10. 1385/IR: 23: 2-3: 147.
27. Jefferies CA, O'Neill LA. Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling? Immunol Lett 2004; 92(1-2): 15-22; PMID: 15081522.
28. Pharmacyclics, Inc., (2012). Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting. [online] Available at: http://ir. pharmacyclics. com/releasedetail. cfm?relea seid=718446 [Accessed 5 Mar. 2014].
29. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21; PMID: 15169797; http://dx. doi. org/10. 1200/JCO. 2004. 02. 106.
30. Taverna C, Voegeli J, Trojan A, Olie RA, von Rohr A. Effective response with bortezomib retreatment in relapsed multiple myeloma-a multicentre retrospective survey in Switzerland. Swiss Med Weekly 2012; 142: w13562; PMID: 22544478.
31. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol 2013; 160: 649-59; PMID: 23293914; http://dx. doi. org/10. 1111/bjh. 12198.
32. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539-49; PMID: 23886836; http://dx. doi. org/10. 1182/blood-2013-06-507947.
33. Tai Y-T, Chang BY, Kong S-Y, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao J-J, Cagnetta A, et al. Bruton's tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-87; PMID: 22689860; http://dx. doi. org/10. 1182/blood-2011-12-396853.
34. McDermott J, Jimeno A. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. Drugs of today (Bar) 2014; 50: 291-300.
35. Cameron F, Sanford M. Ibrutinib: first global approval. Drugs 2014; 74: 263-71; PMID: 24464309; http://dx. doi. org/10. 1007/s40265-014-0178-8.
36. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42; PMID: 23782158; http://dx. doi. org/10. 1056/NEJMoa1215637.
37. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med 2013; 369: 507-16; PMID: 23782157; http://dx. doi. org/10. 1056/NEJMoa1306220.
38. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94; PMID: 23045577; http://dx. doi. org/10. 1200/JCO. 2012. 42. 7906.
39. O'Brien SM, Furman RR, Coutre SE, Flinn I, Burger JA, Blum KA, Sharman JP, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC. "Leukemia. " [Abstract]. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. J Clin Oncol 32: 5s, 2014 (suppl; abstr 7014) ed. Chicago: 2014 ASCO Annual Meeting. (Jun 2014).
40. Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013; 161: 43-56; PMID: 23360303; http://dx. doi. org/10. 1111/bjh. 12206.
41. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356-64; PMID: 18708367; http://dx. doi. org/10. 1158/1541-7786. MCR-08-0108.
42. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99: 14374-9; PMID: 12391322; http://dx. doi. org/10. 1073/pnas. 202445099.
43. -1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006; 20: 1017-27; PMID: 16617327; http://dx. doi. org/10. 1038/sj. leu. 2404200.
44. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92; PMID: 20054396; http://dx. doi. org/10. 1038/nature08638.
45. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2013; 369: 32-42; PMID: 23782158; http://dx. doi. org/10. 1056/NEJMoa1215637.
46. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107: 13075-80; http://dx. doi. org/10. 1073/pnas. 1004594107.
47. Rushworth SA, Bowles KM, Raninga P, MacEwan DJ. NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res 2010; 70: 2973-83; PMID: 20332229; http://dx. doi. org/10. 1158/0008-5472. CAN-09-3407.